Wall Street Zen upgraded shares of Quipt Home Medical (NASDAQ:QIPT - Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.
QIPT has been the subject of a number of other research reports. Canaccord Genuity Group reissued a "hold" rating and issued a $1.70 target price (down previously from $4.00) on shares of Quipt Home Medical in a research note on Tuesday, May 13th. Benchmark reiterated a "buy" rating and set a $4.00 target price (down previously from $6.00) on shares of Quipt Home Medical in a report on Wednesday, May 14th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Quipt Home Medical presently has a consensus rating of "Moderate Buy" and a consensus target price of $3.15.
View Our Latest Stock Report on Quipt Home Medical
Quipt Home Medical Stock Performance
Quipt Home Medical stock traded down $0.0250 during mid-day trading on Friday, reaching $2.2350. 115,593 shares of the company's stock were exchanged, compared to its average volume of 531,491. The company has a quick ratio of 0.75, a current ratio of 1.15 and a debt-to-equity ratio of 0.71. The business's fifty day simple moving average is $2.02 and its 200 day simple moving average is $2.17. Quipt Home Medical has a one year low of $1.35 and a one year high of $3.27. The firm has a market capitalization of $97.09 million, a PE ratio of -9.23 and a beta of 0.59.
Quipt Home Medical (NASDAQ:QIPT - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.10). The company had revenue of $58.30 million during the quarter, compared to analysts' expectations of $80.37 million. Quipt Home Medical had a negative net margin of 4.30% and a negative return on equity of 9.78%. On average, sell-side analysts expect that Quipt Home Medical will post -0.05 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in QIPT. Kanen Wealth Management LLC raised its stake in Quipt Home Medical by 108.4% in the first quarter. Kanen Wealth Management LLC now owns 2,969,541 shares of the company's stock worth $6,919,000 after buying an additional 1,544,529 shares in the last quarter. Pale Fire Capital SE purchased a new stake in Quipt Home Medical during the 1st quarter valued at about $574,000. Strs Ohio purchased a new stake in shares of Quipt Home Medical in the 1st quarter valued at approximately $452,000. Nuveen LLC purchased a new stake in shares of Quipt Home Medical in the 1st quarter valued at approximately $350,000. Finally, Franklin Resources Inc. boosted its position in shares of Quipt Home Medical by 16.8% during the 2nd quarter. Franklin Resources Inc. now owns 824,124 shares of the company's stock worth $1,475,000 after purchasing an additional 118,332 shares during the period. Hedge funds and other institutional investors own 42.85% of the company's stock.
Quipt Home Medical Company Profile
(
Get Free Report)
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment.
Featured Articles
Before you consider Quipt Home Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quipt Home Medical wasn't on the list.
While Quipt Home Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.